Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Top Democrats: Trump Admin’s COVID-19 Insurance Guidance Poses ‘Serious Threat’

Executive Summary

Democratic lawmakers argue the Trump administration’s interpretation of how COVID-19 testing is covered by private insurers runs contrary to the Families First Act and CARES Act. They want the administration to update a FAQ sheet that eliminates certain prerequisites that would qualify patients to be reimbursed for the tests.

You may also be interested in...



Senators: Lack Of Full Coverage For Coronavirus Testing In US A Barrier To COVID-19 Surveillance

Asymptomatic people in the US are receiving bills for COVID-19 tests they get for work or travel – and some are refusing tests to avoid the costs, senators tell health care agency officials.

Massive Family Dollar Rat Infestation Leads To Multi-State Recall

The US FDA found more than 2,000 rats at an Arkansas Family Dollar distribution center, leadingto a six-state recall for products including feminine hygiene products, contact lens cleaners and face masks.

Digital Health Roundup: Exec Chats With Illumina, Bloom, AngelMed; M&A, Funding; FDA Down-Classifies Apps

In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights IBM Watson Health’s divestiture and other financing news, Exec Chats with Illumina, AngelMed and Bloom, Philips’ new hand-held ultrasound device and autonomous robotic surgery, as well as the latest FDA news on digital health.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT142392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel